Subcutaneous gonadotropin-releasing hormone agonist injection for hormone-sensitive cancers including prostate and breast. Procured by oncology units in medical centers for therapeutic regimens. Distributed by biotech firms to healthcare providers treating endocrine-dependent malignancies.